FDA green-lights Infinitt cardiac display, analysis package

Lisa Fratt | | Health Imaging | Screening
Infinitt's Xelis Cardiac, a 2D, 3D and 4D display and analysis tool for coronary CT angiography and left ventricle analysis, has received clearance from the FDA.

Xelis Cardiac can be used as an integrated system with Infinitt's web-based PACS or as a stand-alone system, allowing any third-party PACS user to query, view and analyze DICOM studies.

The package includes three diagnostic modules: vessel analysis, functional ventricle analysis and calcium scoring.

Infinitt, the Phillipsburg, N.J.-based developer of image and information management systems for healthcare, added that the Xelis Calcium Scoring system is currently under FDA review.

 

 


Lisa Fratt

Related Content

AI beats standard regression models at predicting lung cancer risk
AI reduces CT lung cancer screening workload by nearly 80%
Abbreviated MRI protocols present suitable alternatives for liver cancer screening
Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk

Around the web

Cardiovascular Business
ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.